Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dipeptidase 2 (DPEP2)
- Target
- DPEP2
- Molecular classification
- Enzyme, Membrane-bound dipeptidase, Metalloexopeptidase
01
Overview
Dipeptidase 2 (DPEP2) is a membrane-bound dipeptidase enzyme anchored to the plasma membrane via glycosyl phosphatidylinositol[1][3]. It hydrolyzes a variety of dipeptides, including leukotriene D4 (LTD4), beta-lactam rings of some antibiotics, and cystinyl-bis-glycine. DPEP2 is highly expressed in lung, heart, and testis, with roles in regulating cell migration and invasion through effects on epithelial-mesenchymal transition (EMT), cancer stem cell transformation, and chemotherapy response in lung adenocarcinoma[1]. DPEP2 also acts as a key regulator in inflammatory signal transduction in macrophages by binding and modulating MAP3K members that activate NF-κB and p38 MAPK pathways[2]. Loss or degradation of DPEP2 (e.g., via Trim32-mediated ubiquitination) enhances pro-inflammatory signaling in macrophages[2]. DPEP2 serves as both a prognostic biomarker and potential therapeutic target in cancer and inflammation.
- Other names
- DPEP2Dipeptidase 2UNQ284/PRO323MBD2
02
Mechanism of action
Cisplatin: increased sensitivity via inhibition of EMT and stem cell transformation markers. Beta-lactam antibiotics: hydrolysis of the beta-lactam ring.
03
Biological functions
Dipeptide hydrolysis (including leukotriene D4, beta-lactam ring of some antibiotics, cystinyl-bis-glycine)Regulation of cell migration and invasion (via effects on epithelial-mesenchymal transition)Regulation of inflammatory signal transduction in macrophages (affecting NF-κB and p38 MAPK signaling)Modulation of cancer stem cell transformation, chemo-sensitivity
04
Disease associations
Cancer (notably lung adenocarcinoma, cell migration, EMT, cisplatin resistance)Inflammation (regulation of macrophage-mediated intestinal inflammation)Orange allergyLeukoencephalopathy, cystic, without megalencephaly
05
Safety considerations
Potential impact on chemotherapy resistance (via EMT and stem cell traits)Role in inflammation requires further study for therapeutic targeting
06
Interacting drugs
Cisplatin
1 more in the full profile.
07
Biomarkers
DPEP2 (prognostic marker in lung adenocarcinoma)E-cadherin, N-cadherin, vimentin, α-SMA (downstream markers modulated by DPEP2)CD44, CD133 (cancer stem cell markers, affected by DPEP2 expression)
Beyond the preview
Go deeper on Dipeptidase 2 (DPEP2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dipeptidase 2 (DPEP2).